The independent medical news service

Black men with localized prostate cancer fare better than their White counterparts after definitive radiotherapy, suggests a meta-analysis.

The addition of enzalutamide rather than a standard nonsteroidal anti-androgen to testosterone suppression is associated with worsening of some health-related quality of life function and symptom scores in men with metastatic hormone-sensitive prostate cancer, report the ENZAMET researchers.

Recovery of sexual function varies widely following radical prostatectomy at both the patient and surgeon level, but is not associated with surgeon case volume, US researchers report.

Postdiagnostic metformin or statin use may reduce the risk for death among people with advanced prostate cancer, suggests an analysis of US Veteran Health Administration data.

Around 10% of men with localized prostate cancer experience treatment-related regret but this rate varies by treatment modality and is mediated by posttreatment functional outcomes and patient expectations, study findings indicate.

Rates of prostate-specific antigen testing have increased significantly since 2017, following the publication of guidelines reversing a previous recommendation against routine prostate cancer screening in young men, US researchers report.

Men who carry germline mismatch repair pathogenic variants in the MSH2 and MSH6 genes, typically associated with Lynch syndrome, have a significantly higher incidence of prostate cancer than noncarriers, show early data from the IMPACT study.

Results of the PRINCE trial point to the potential of LuPSMA plus pembrolizumab for the treatment of metastatic castration-resistant prostate cancer with high expression of PSMA.

Supplementing androgen deprivation therapy with 2 years of an abiraterone acetate-based regimen significantly boosts the survival of men with high-risk nonmetastatic prostate cancer, show STAMPEDE results.

The addition of abiraterone acetate to standard therapy with docetaxel plus androgen deprivation therapy significantly improves the overall survival of patients with de novo metastatic castration-sensitive prostate cancer, report the PEACE-1 investigators.

The final analysis of the ARCHES trial has demonstrated a significant overall survival boost with the addition of enzalutamide instead of placebo to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting.

Slow recruitment and low event rates have led to early termination of the PRONOUNCE trial, which hoped to determine the relative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists in men with prostate cancer.

The number of new cancer diagnoses during the first year of the COVID-19 pandemic was lower than in the prepandemic period, report US researchers.

Phase 2 study data show that the PARP inhibitor talazoparib has antitumor activity in men with heavily pretreated metastatic castration-resistant prostate cancer bearing DNA damage response alterations in genes associated with homologous recombination repair.

Men with localized prostate cancer undergoing active surveillance who follow a high-intensity interval training regimen can expect improvements in cardiorespiratory fitness and indicators of biochemical progression, early findings indicate.

The Stockholm3 risk prediction tool performs at least as well as prostate-specific antigen screening for the detection of clinically significant prostate cancer, research suggests.

A US study has found no significant difference in outcomes between African–American and White men undergoing active surveillance for intermediate-risk prostate cancer.

The addition of bone resorption inhibitors to abiraterone acetate plus prednisone is associated with improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases, especially if they have high-volume disease, researchers report.

Nonmetastatic castration-resistant prostate cancer patients aged 80 years and older benefit from treatment with second-generation androgen receptor inhibitors, suggests a pooled analysis of three trials.

Black men with nonmetastatic prostate cancer were significantly less likely than their White counterparts to undergo prostatectomy during the initial wave of the COVID-19 pandemic, reports a US research team.